Residency · Residency · Radiation Oncology
Larynx Preservation: Radiation vs. Surgery for Laryngeal and Hypopharyngeal Cancer
Overview
Organ preservation using radiation-based therapy has become a central approach in managing laryngeal and hypopharyngeal cancers. The primary goal is to achieve a cure while maintaining a functional larynx, which includes preserving voice quality, swallowing ability, and airway protection. Landmark clinical trials such as the VA Laryngeal Study, RTOG 91-11, and GORTEC have established chemoradiation as a standard alternative to total laryngectomy. However, careful patient selection is essential because organ preservation is not suitable for all cases. In particular, patients presenting with laryngeal dysfunction or T4a disease involving cartilage destruction are generally not candidates for preservation strategies.
Anatomy and Function
The larynx is anatomically divided into three subsites: the supraglottis, which includes the epiglottis, aryepiglottic folds, and false vocal cords; the glottis, comprising the true vocal cords and the anterior and posterior commissures; and the subglottis. The hypopharynx consists of the pyriform sinuses, the posterior pharyngeal wall, and the postcricoid region. Functional preservation of the larynx involves more than just maintaining its anatomical structure; it requires preserving voice quality, enabling swallowing without aspiration, and ensuring airway patency without dependence on a tracheostomy.
Landmark Clinical Trials
VA Laryngeal Cancer Study (1991)
This Phase III trial compared induction chemotherapy using cisplatin and 5-fluorouracil (5-FU) for three cycles followed by radiation therapy (RT) in responders, against total laryngectomy followed by adjuvant RT in patients with advanced (stage III-IV) laryngeal cancer. The study demonstrated equivalent overall survival (OS) between the two arms, with approximately 68% survival at two years. Importantly, the induction chemotherapy arm achieved a 64% larynx preservation rate, establishing that organ preservation is feasible without compromising survival. Notably, this study did not include concurrent chemoradiation.
RTOG 91-11 (2003, updated 2013)
This Phase III, three-arm trial enrolled patients with stage III-IV (excluding T1) laryngeal cancer and compared three treatment strategies: induction cisplatin/5-FU followed by RT, concurrent cisplatin with RT, and RT alone, all delivering 70 Gy. The primary endpoint was larynx preservation rate. Results showed that concurrent chemoradiation therapy (CRT) provided superior locoregional control at 78%, compared to 61% with induction chemotherapy and 56% with RT alone. At 10 years, larynx preservation was highest in the concurrent CRT arm at 82%, versus 68% for induction and 64% for RT alone. Overall survival did not differ significantly among the groups at 10 years. However, a concerning finding was an increased number of late deaths unrelated to cancer or treatment in the concurrent CRT group, possibly due to long-term swallowing dysfunction leading to aspiration. This trial established concurrent CRT as the standard organ-preservation regimen.
GORTEC 96-01
This Phase III trial compared induction chemotherapy regimens for laryngeal and hypopharyngeal cancer. Patients received either TPF (docetaxel, cisplatin, and 5-FU) or PF (cisplatin and 5-FU) induction followed by RT. The TPF regimen resulted in higher response rates and better larynx preservation, supporting its use as the preferred induction chemotherapy if induction is chosen.
| Trial | Arms | Larynx Preservation | Overall Survival | Key Finding |
|---|---|---|---|---|
| VA Laryngeal Study (1991) | Induction PF → RT vs. TL + RT | 64% (induction arm) | Equivalent (~68% at 2 yr) | Organ preservation feasible without OS compromise |
| RTOG 91-11 (2003/2013) | Concurrent CRT vs. Induction PF → RT vs. RT alone | 82% vs. 68% vs. 64% (10 yr) | No significant difference | Concurrent CRT superior for larynx preservation |
| GORTEC 96-01 | TPF → RT vs. PF → RT | TPF superior | TPF superior | TPF preferred induction regimen |
Patient Selection
Favorable for Organ Preservation
Patients with T2-T3 glottic or supraglottic tumors, good pre-treatment laryngeal function characterized by mobile vocal cords and functional swallowing, and adequate pulmonary function to tolerate aspiration risk are suitable candidates for organ preservation. Additionally, motivated patients who are committed to follow-up and rehabilitation and those without cartilage destruction on imaging are favorable for this approach.
Unfavorable for Organ Preservation (Consider Primary Surgery)
Patients with T4a tumors exhibiting cartilage destruction through the thyroid or cricoid cartilage are generally excluded from organ preservation strategies, as reflected in the RTOG 91-11 trial, which showed lower preservation rates in this group. Those presenting with pre-treatment laryngeal dysfunction, such as fixed vocal cords with aspiration or stridor requiring tracheostomy, large-volume T4a disease with extralaryngeal spread, poor pulmonary reserve unable to tolerate aspiration, or inability to comply with intensive treatment and surveillance should be considered for primary surgery.
Radiation Therapy Technique
Definitive RT for Early Glottic Cancer (T1-T2 N0)
For T1N0 glottic cancer, radiation therapy alone is the standard treatment, achieving 5-year local control rates of 85-95%. The typical dose ranges from 63 to 66 Gy delivered in 28 to 33 fractions at 2.0 to 2.25 Gy per fraction. Treatment fields are small, consisting of opposing lateral beams covering only the true vocal cords, typically measuring 5x5 to 6x6 cm. Elective nodal irradiation is not necessary due to the low nodal risk (<5%) in T1 glottic cancer. For T2N0 glottic tumors, either RT alone or concurrent chemoradiation is used, especially for larger tumors with impaired cord mobility. The dose ranges from 65.25 to 70 Gy in 29 to 35 fractions, and elective nodal coverage may be required if there is supraglottic extension.
Concurrent CRT for Advanced Laryngeal/Hypopharyngeal Cancer
The standard regimen delivers 70 Gy in 35 fractions combined with concurrent cisplatin, either 100 mg/m² every three weeks for three cycles or 40 mg/m² weekly. Target volumes include the gross tumor volume (GTV), defined by imaging (CT and MRI) and clinical examination, encompassing the primary tumor and involved lymph nodes. The high-risk clinical target volume (CTV) includes the GTV plus a 1 cm margin, while elective CTV covers bilateral nodal levels at risk, typically levels II-IV; level VI is included for subglottic extension, and retropharyngeal nodes are targeted for hypopharyngeal or supraglottic tumors. Intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) is standard, allowing sparing of the parotid glands and reduction of dose to the pharyngeal constrictors. For lateralized tumors, it is advisable to avoid high-dose irradiation of the contralateral uninvolved neck when safe.
Altered Fractionation
Hyperfractionation, delivering 1.2 Gy twice daily to a total of 81.6 Gy, and accelerated fractionation schedules have demonstrated improved locoregional control in meta-analyses such as the MARCH meta-analysis. This benefit is most evident in the absence of concurrent chemotherapy. In clinical practice, however, concurrent chemoradiation with standard fractionation remains the most common approach.
Salvage Laryngectomy
Salvage laryngectomy is required in 15-30% of patients following chemoradiation failure. This procedure carries higher complication rates compared to primary laryngectomy, with pharyngocutaneous fistula occurring in 15-30% of cases and other wound complications being common. It is important to distinguish salvage laryngectomy, performed for recurrent or persistent tumor, from functional laryngectomy, which is done for a non-functioning larynx after chemoradiation despite tumor control. Long-term swallowing dysfunction after chemoradiation may eventually necessitate laryngectomy even without evidence of recurrence.
Hypopharyngeal Cancer
Hypopharyngeal cancer generally has a poorer prognosis than laryngeal cancer, with a higher likelihood of presenting with advanced nodal disease and a greater rate of distant metastasis. The EORTC 24891 trial demonstrated that an organ preservation approach using induction PF chemotherapy followed by radiation in responders, with surgery reserved for non-responders, achieved overall survival equivalent to primary surgery followed by radiation. Concurrent chemoradiation is now the standard organ-preservation approach for resectable hypopharyngeal cancer.
<image>A three-panel illustration showing the anatomy of the larynx in sagittal cross-section with the three subsites (supraglottis, glottis, subglottis) labeled. Panel 1 shows a T1 glottic cancer confined to one true vocal cord with the small opposing lateral radiation fields (5x5 cm). Panel 2 shows a T3 supraglottic cancer with pre-epiglottic space invasion and bilateral level II-IV nodal fields required. Panel 3 shows a T4a laryngeal cancer with cartilage destruction, indicating primary total laryngectomy as preferred over organ preservation.</image>
<image>A summary graphic of the RTOG 91-11 trial results at 10 years. Three bar groups compare the three arms (induction chemo then RT, concurrent CRT, RT alone) for four endpoints: locoregional control, larynx preservation, overall survival, and late non-cancer deaths. The concurrent CRT arm shows the highest locoregional control and larynx preservation but comparable OS and a trend toward more late deaths. Key percentages are annotated on each bar.</image>
Key Clinical Pearls
Organ preservation must be understood as functional organ preservation. Preserving a larynx that is non-functional and leads to chronic aspiration and eventual laryngectomy is a worse outcome than primary surgical management. The RTOG 91-11 trial established concurrent chemoradiation as superior to induction chemotherapy followed by radiation for larynx preservation. However, the unexplained excess of late non-cancer deaths in the concurrent arm highlights the critical importance of long-term swallowing rehabilitation. T1N0 glottic cancer is among the most curable cancers in oncology, with local control rates exceeding 90% using radiation therapy alone. Treatment with small-field opposing lateral beams is simple, effective, and associated with minimal morbidity; thus, overcomplicating the treatment plan should be avoided. For patients with T4a disease involving cartilage destruction through the thyroid or cricoid cartilage, primary total laryngectomy followed by adjuvant radiation therapy, with or without cisplatin based on pathological risk factors, offers the best oncologic outcome. Pre-treatment speech and swallowing evaluations should be standard for all patients considered for organ preservation, as documenting baseline function is essential for post-treatment comparison and rehabilitation planning. Finally, completing all three planned cycles of concurrent cisplatin is associated with better outcomes; therefore, clinicians should aim for at least two cycles, achieving a cumulative dose of at least 200 mg/m², even if the third cycle must be modified or omitted.
References
- Department of Veterans Affairs Laryngeal Cancer Study Group. "Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer." N Engl J Med. 1991;324(24):1685-1690.
- Forastiere AA et al. "Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer." J Clin Oncol. 2013;31(7):845-852.
- Pointreau Y et al. "Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation." J Natl Cancer Inst. 2009;101(7):498-506.
- Lefebvre JL et al. "Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial." J Natl Cancer Inst. 1996;88(13):890-899.
- Pignon JP et al. "Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients." Radiother Oncol. 2009;92(1):4-14.
